How is ru486 used

The Second Stage: Misoprostol administered in tablet form is widely used in surgical termination of pregnancies to increase the safety of the procedure and reduce the risk of bleeding.

For medical abortion it is administered approximately 48 hours after the Mifepristone and causes the uterus to contract, assisting in the expulsion of the embryo and associated tissue. At this appointment an ultrasound and possibly a blood test should be done to make sure the termination is complete. In about 2 percent of cases, the abortion is not complete and a surgical termination is needed. Mifepristone is not recommended for all women and so a thorough medical history needs to be taken to rule out anything that may mean it would be unsafe for you to take it including if you — o have a blood disorder o have high blood pressure o have an ectopic tubal pregnancy o are more than 9 weeks pregnant o have allergic reaction to medications containing mifepristone o are fitted with an intrauterine device IUD.

The device would need to be removed before taking mifepristone. Some private insurance plans may cover the drug. Please consult your healthcare provider for advice about a specific medical condition. This document was last reviewed on: March 23, Text Size. Jump to body content What is the abortion drug RU , and how does it work? What is the abortion drug RU , and how does it work?

Two drugs are used in a medical abortion: mifepristone RU , and misoprostol. This document was last reviewed on: March 23, Jump to top page. In France the gestational age limit is 49 days of amenorrhea, in the UK and Sweden it is 63 days. This procedure involves an initial administration of RU with a follow-up visit in 2 days.

If the woman has not aborted, she is given a dose of prostaglandin and observed for about 4 hours, during which time most women abort. A return visit is scheduled in 2 weeks. The procedure has recently been improved by the use of an oral pill, misoprostol, as the prostaglandin. The mechanism of action involves the intracellular receptors of the antagonized hormones progesterone and glucocorticosteroids. At the molecular level, the most important features are high binding affinity to the receptor, interaction of the phenylaminodimethyl group in the 11 beta-position with a specific region of the receptor binding pocket, and RUinduced transconformation differences in the ligand-binding domain.

These particularities have consequences at different steps of the receptor function as compared with agonists.